Login to Your Account



Vertex, Aventis Halt Pralnacasan Development To Gauge Toxicity

By Kim Coghill


Wednesday, November 12, 2003
Wall Street was unforgiving Tuesday, one day after Vertex Pharmaceuticals Inc. and partner Aventis SA voluntarily stopped a Phase IIb trial of a rheumatoid arthritis candidate on news that a related animal toxicology study turned up liver abnormalities. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription